Targeting Unique Features of Quiescent Cancer Stem Cells to Overcome Resistance and Recurrence in Cancer Therapy: A Review

References (82)

1. 1 Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [DOI]
2. 2 THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASE [DOI]
3. 3 A cell initiating human acute myeloid leukaemia after transplantation into SCID mice [DOI]
4. 4 mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery [DOI]
5. 5 Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control [DOI]
6. 6 The emerging mechanisms of isoform-specific PI3K signalling [DOI]
7. 7 Cancer Stem Cells: Current Status and Evolving Complexities [DOI]
8. 8 PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein Kinase [DOI]
9. 9 Can we safely target the WNT pathway? [DOI]
10. 10 The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors [DOI]
11. 11 Wnt/Frizzled Activation of Rho Regulates Vertebrate Gastrulation and Requires a Novel Formin Homology Protein Daam1 [DOI]
12. 12 Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT [DOI]
13. 13 Dishevelled: The hub of Wnt signaling [DOI]
14. 14 Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance [DOI]
15. 15 The DREAM complex: master coordinator of cell cycle-dependent gene expression [DOI]
16. 16 Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer [DOI]
17. 17 Prickle Mediates Feedback Amplification to Generate Asymmetric Planar Cell Polarity Signaling [DOI]
18. 18 Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy [DOI]
19. 19 STAT signaling in head and neck cancer [DOI]
20. 20 The metastasis-promoting roles of tumor-associated immune cells [DOI]
21. 21 Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis [DOI]
22. 22 Cancer Stem Cells: The Promise and the Potential [DOI]
23. 23 Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells [DOI]
24. 24 Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice [DOI]
25. 25 New Insights into the Mechanism of Wnt Signaling Pathway Activation [DOI]
26. 26 Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments [DOI]
27. 27 Clone- and Gene-Specific Aberrations of Parental Imprinting in Human Induced Pluripotent Stem Cells [DOI]
28. 28 PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype [DOI]
29. 29 The Molecular Basis of Pluripotency in Mouse Embryonic Stem Cells [DOI]
30. 30 Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer [DOI]
31. 31 Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer [DOI]
32. 32 Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies [DOI]
33. 33 A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288 [DOI]
34. 34 The Cyclin-dependent Kinase Inhibitor p27Kip1 Is Stabilized in G0 by Mirk/dyrk1B Kinase [DOI]
35. 35 Stability elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-dependent polymerization [DOI]
36. 36 Mirk/Dyrk1B Mediates Survival during the Differentiation of C2C12Myoblasts [DOI]
37. 37 IL6/JAK1/STAT3 Signaling Blockade in Endometrial Cancer Affects the ALDHhi/CD126+ Stem-like Component and Reduces Tumor Burden [DOI]
38. 38 Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures [DOI]
39. 39 The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network [DOI]
40. 40 Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal [DOI]
41. 41 Design and Synthesis of a Library of Lead-Like 2,4-Bisheterocyclic Substituted Thiophenes as Selective Dyrk/Clk Inhibitors [DOI]
42. 42 Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2 [DOI]
43. 43 Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse [DOI]
44. 44 Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids [DOI]
45. 45 PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model [DOI]
46. 46 Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis [DOI]
47. 47 MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling [DOI]
48. 48 Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms [DOI]
49. 49 The normal function of the cancer kinase Mirk/dyrk1B is to reduce reactive oxygen species [DOI]
50. 50 Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer [DOI]
51. 51 Cancer stem cells revisited [DOI]
52. 52 An inhibitor of oxidative phosphorylation exploits cancer vulnerability [DOI]
53. 53 Visualization and targeting of LGR5+ human colon cancer stem cells [DOI]
54. 54 Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy [DOI]
55. 55 Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review) [DOI]
56. 56 Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling [DOI]
57. 57 Cancer metabolism and mitochondria: Finding novel mechanisms to fight tumours [DOI]
58. 58 PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials [DOI]
59. 59 Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer [DOI]
60. 60 Akt as a target for cancer therapy: more is not always better (lessons from studies in mice) [DOI]
61. 61 Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview [DOI]
62. 62 The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities [DOI]
63. 63 Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma [DOI]
64. 64 Quiescent Cancer Cells—A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse [DOI]
65. 65 YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification [DOI]
66. 66 YES1: A Novel Therapeutic Target and Biomarker in Cancer [DOI]
67. 67 Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy [DOI]
68. 68 Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia [DOI]
69. 69 Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer [DOI]
70. 70 A wake‐up call to quiescent cancer cells – potential use of DYRK 1B inhibitors in cancer therapy [DOI]
71. 71 YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics [DOI]
72. 72 OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells [DOI]
73. 73 Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells [DOI]
74. 74 Mitochondria in cancer: clean windmills or stressed tinkerers? [DOI]
75. 75 Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells [DOI]
76. 76 Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis [DOI]
77. 77 Sorting‐free metabolic profiling uncovers the vulnerability of fatty acid β‐oxidation in in vitro quiescence models [DOI]
78. 78 Descriptive Proteome Analysis to Investigate Context-Dependent Treatment Responses to OXPHOS Inhibition in Colon Carcinoma Cells Grown as Monolayer and Multicellular Tumor Spheroids [DOI]
79. 79 Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient [DOI]
80. 80 Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal [DOI]
81. 81 EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter [DOI]
82. 82 NLRC3 regulates cellular proliferation and apoptosis to attenuate the development of colorectal cancer [DOI]

Cited by 7

Showing 2 of 7 known citations — external sources report more than can currently be individually listed.

Related research

• Cardiotoxicity of Targeted Therapies in Non-Hematologic Cancers: Mechanisms, Risks and Monitoring — shares topic coverage
• Nanoparticles as a Local Drug Delivery System: A Scoping Review — shares topic coverage
• Treatment of Metastatic Renal Cell Carcinoma: A Comprehensive Review and Indian Perspective — shares topic coverage
• Decoding Tumor Drug Resistance: Present Status and Future Landscapes — shares topic coverage
• Advances in Oral and Maxillofacial Cancer Research: A Comprehensive Review — shares topic coverage